Lantern Pharma (LTRN) Tops Q2 EPS by 2c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival shares drop despite earnings beat on weak guidance
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance